ESC 365 - NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

Open Access

NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

Session: Late-breaking clinical trials in chronic heart failure

Topic: Treatment

Speaker: Doctor R. Hajjar (Boston, US)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Roger J Hajjar

Massachusetts General Brigham - Harvard Medical School, Boston (United States of America)

6 presentations

0 follower

5 more presentations in this session

Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction. REDICAE trial

Speaker: Doctor J. Torres Zamudio (Cordoba, ES)

Oral iron supplementation with ferric maltol improves iron deficiency anaemia in patients with chronic heart failure

Speaker: Professor T. Kempf (Hannover, DE)

Gene therapy for heart failure with preserved ejection fraction

Speaker: Doctor M. Fudim (Durham, US)

Finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomized placebo-controlled mechanistic trial (FIVE-STAR)

Speaker: Professor A. Tanaka (Saga, JP)

Cardio-microcurrent device for chronic heart failure: results from the C-MIC II randomized controlled trial

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

Late-breaking clinical trials in chronic heart failure

Speakers: Doctor R. Hajjar, Doctor J. Torres Zamudio, Professor T. Kempf, Doctor M. Fudim, Professor A. Tanaka...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources